Compare Amgen, Inc. (AMGN) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Lowe`s Companies Inc — how do they compare? Amgen, Inc. trades at $362.08 (market cap $196.12B), while Lowe`s Companies Inc trades at $212.6 (market cap $118.66B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | LOW | |
|---|---|---|
Market Cap | $196.12B | $118.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $287.39 |
52-Week Low | $271.18 | $206.62 |
Enterprise Value | $241.41B | $160.42B |
Dividend Yield | 2.77% | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Lowe's Companies (LOW) trades at $211.63, down 0.64% on the day, with a bearish technical signal from moving averages. The company maintains solid fundamentals with a P/E of 17.89 and net income margin of 7.51%, having beaten earnings estimates for three consecutive quarters. Revenue declined to $83.67 billion in 2025 but shows stabilization with 2026 projections of $88.4 billion. Analyst consensus remains strongly bullish with a $260.88 price target, representing 23% upside potential from current levels.
LOW presents a compelling value opportunity with strong dividend growth and consistent earnings performance, though near-term headwinds include housing market sensitivity and competitive pressures. The stock's current valuation discount to analyst targets and improving cash flow trends support a positive medium-term outlook, balanced by technical weakness and macroeconomic uncertainties affecting the home improvement sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
